Search | Net Pals

MatthewJohnson added blog Other
2026-10-23 21:49:05 - Translate -

HSBC starts Constellation Energy (CEG) and Vistra (VST) at buy and models $14 billion of buybacks at each
HSBC began coverage of Constellation Energy Corporation (CEG) at buy with a $335 target and Vistra Corp. (VST) at buy with a $190 target, forecasting earnings per share growth of 19% and 21% a year to 2030. HSBC has opened coverage of two of the largest US power generators with buy ratings. It set a $335 target on Constellation Energy Corporation (CEG) and a $190 target on Vistra Corp. (VST)....

0 Comments 0 Shares 7 Views 0 Reviews

Please log in to like, share and comment!
BrianThompson added blog Other
2026-10-23 15:52:57 - Translate -

JPMorgan cuts DuPont de Nemours Inc. (DD) to neutral, saying the restocking lift has largely played out
JPMorgan analyst Chigusa Katoku lowered her DuPont de Nemours Inc. (DD) target to $145 from $172, citing slower short-cycle restocking, months after a second quarter that beat the company's own guidance. JPMorgan analyst Chigusa Katoku cut DuPont de Nemours Inc. (DD) to neutral from overweight on Friday and lowered her price target to $145 from $172. Investing.com reported the call, which...

0 Comments 0 Shares 37 Views 0 Reviews

Please log in to like, share and comment!
RobertMitchell added blog Health
2026-10-23 19:35:08 - Translate -

Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease tests
Roth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...

0 Comments 0 Shares 7 Views 0 Reviews

Please log in to like, share and comment!
RichardMoore added blog Other
2026-10-23 18:19:22 - Translate -

Piper Sandler cuts Globe Life (GL) to Neutral as Medicare Supplement claims cloud its 2027 outlook
Piper Sandler moved Globe Life Inc. (GL) to Neutral from Overweight and cut its target to $165 from $200, citing medical claims and 2027 guidance after a quarter in which health benefits rose 19%. Piper Sandler downgraded Globe Life Inc. (GL) to Neutral from Overweight on Friday and cut its price target to $165 from $200, according to Investing.com. The firm said the insurer lost much of the...

0 Comments 0 Shares 9 Views 0 Reviews

Please log in to like, share and comment!